Exploring Jing Si Herbal Tea as an Added Treatment for Chronic Obstructive Pulmonary Disease COPD

What this Trial Is About

Chronic obstructive pulmonary disease COPD is a common lung condition that causes airflow blockage and breathing difficulties, significantly affecting patients quality of life. This research aims to evaluate the potential benefits of Jing Si Herbal Tea JSHT, known for its anti-inflammatory properties, as an additional treatment for COPD. The study focuses on patients in both the exacerbation and stable phases of COPD and compares standard treatment alone to standard treatment combined with JSHT. Participants are divided into four groups those with COPD exacerbation receiving JSHT or a placebo, and those with stable COPD receiving JSHT or a placebo that mimics JSHT. The trial investigates how JSHT affects inflammation and lung tissue damage, including its impact on cellular markers and inflammatory molecules. The study involves randomized assignment to these groups and uses a single-blind design. During the study, participants undergo assessments of health-related quality of life using tools like the COPD Assessment Test CAT, Modified Medical Research Council mMRC scale, and Brief Symptom Rating Scale BSRS-5 at the start and after three months of treatment. Blood tests and cellular studies will also be conducted to monitor inflammation and immune responses. The total participation time includes baseline and three months of treatment, with ongoing monitoring of symptoms and inflammatory markers to evaluate JSHT as a possible supportive therapy for COPD.

Therapeutic Effects of Jing Si Herbal Tea for COPD